Signal Transduction and Targeted Therapy,
Journal Year:
2022,
Volume and Issue:
7(1)
Published: July 19, 2022
Recently,
a
large
number
of
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
variants
continuously
emerged
and
posed
major
threat
to
global
public
health.
Among
them,
particularly,
Omicron
variant
(B.1.1.529),
first
identified
in
November
2021,
carried
numerous
mutations
its
spike
protein
(S),
then
quickly
spread
around
the
world.
Currently,
has
expanded
into
more
than
one
hundred
sublineages,
such
as
BA.1,
BA.2,
BA.2.12.1,
BA.4
BA.5,
which
have
already
become
globally
dominant
variants.
Different
from
other
concern
(VOCs)
SARS-CoV-2,
sublineages
exhibit
increased
transmissibility
immune
escape
neutralizing
antibodies
generated
through
previous
infection
or
vaccination,
caused
re-infections
breakthrough
infections.
In
this
prospective,
we
focused
on
origin,
virological
features,
evasion
intervention
will
benefit
development
next-generation
vaccines
therapeutics,
including
pan-sarbecovirus
universal
anti-CoV
combat
currently
circulating
future
emerging
well
SARS-CoV-2
Canadian Medical Association Journal,
Journal Year:
2022,
Volume and Issue:
194(7), P. E242 - E251
Published: Jan. 19, 2022
The
role
of
remdesivir
in
the
treatment
patients
hospital
with
COVID-19
remains
ill
defined
a
global
context.
World
Health
Organization
Solidarity
randomized
controlled
trial
(RCT)
evaluated
across
many
countries,
Canada
enrolling
using
an
expanded
data
collection
format
Canadian
Treatments
for
(CATCO)
trial.
We
report
on
findings,
additional
demographics,
characteristics
and
clinical
outcomes,
to
explore
potential
differential
effects
different
health
care
systems.
Nature Communications,
Journal Year:
2021,
Volume and Issue:
12(1)
Published: June 7, 2021
Prognostic
characteristics
inform
risk
stratification
in
intensive
care
unit
(ICU)
patients
with
coronavirus
disease
2019
(COVID-19).
We
obtained
blood
samples
(n
=
474)
from
hospitalized
COVID-19
123),
non-COVID-19
ICU
sepsis
25)
and
healthy
controls
30).
Severe
acute
respiratory
syndrome
2
(SARS-CoV-2)
RNA
was
detected
plasma
or
serum
(RNAemia)
of
when
neutralizing
antibody
response
low.
RNAemia
is
associated
higher
28-day
mortality
(hazard
ratio
[HR],
1.84
[95%
CI,
1.22-2.77]
adjusted
for
age
sex).
comparable
performance
to
the
best
protein
predictors.
Mannose
binding
lectin
pentraxin-3
(PTX3),
two
activators
complement
pathway
innate
immune
system,
are
positively
mortality.
Machine
learning
identified
'Age,
RNAemia'
PTX3'
as
binary
signatures
In
longitudinal
comparisons,
have
a
distinct
proteomic
trajectory
mortality,
recovery
many
liver-derived
proteins
indicating
survival.
Finally,
system
galectin-3-binding
(LGALS3BP)
interaction
partners
SARS-CoV-2
spike
glycoprotein.
LGALS3BP
overexpression
inhibits
spike-pseudoparticle
uptake
spike-induced
cell-cell
fusion
vitro.
Annals of the Rheumatic Diseases,
Journal Year:
2022,
Volume and Issue:
81(12), P. 1628 - 1639
Published: Feb. 23, 2022
The
first
EULAR
provisional
recommendations
on
the
management
of
rheumatic
and
musculoskeletal
diseases
(RMDs)
in
context
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2),
largely
based
expert
opinion,
were
published
June
2020.
Since
then,
an
unprecedented
number
clinical
studies
have
accrued
literature.
Several
SARS-CoV-2
vaccines
been
approved
for
population-wide
vaccination
programmes
EULAR-affiliated
countries.
Studies
regarding
patients
with
(inflammatory)
RMDs
released
their
results
or
are
underway.
found
it
opportune
to
carefully
review
what
extent
initially
consensus
stood
test
time,
by
challenging
them
recently
accumulated
body
scientific
evidence,
incorporating
evidence-based
advice
vaccination.
started
a
formal
(first)
update
January
2021,
performed
systematic
literature
according
EULAR’s
standard
operating
procedures
completed
set
updated
overarching
principles
July
2021.
Two
points
consider
added
November
because
recent
developments
pertaining
additional
doses.
Signal Transduction and Targeted Therapy,
Journal Year:
2022,
Volume and Issue:
7(1)
Published: July 19, 2022
Recently,
a
large
number
of
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
variants
continuously
emerged
and
posed
major
threat
to
global
public
health.
Among
them,
particularly,
Omicron
variant
(B.1.1.529),
first
identified
in
November
2021,
carried
numerous
mutations
its
spike
protein
(S),
then
quickly
spread
around
the
world.
Currently,
has
expanded
into
more
than
one
hundred
sublineages,
such
as
BA.1,
BA.2,
BA.2.12.1,
BA.4
BA.5,
which
have
already
become
globally
dominant
variants.
Different
from
other
concern
(VOCs)
SARS-CoV-2,
sublineages
exhibit
increased
transmissibility
immune
escape
neutralizing
antibodies
generated
through
previous
infection
or
vaccination,
caused
re-infections
breakthrough
infections.
In
this
prospective,
we
focused
on
origin,
virological
features,
evasion
intervention
will
benefit
development
next-generation
vaccines
therapeutics,
including
pan-sarbecovirus
universal
anti-CoV
combat
currently
circulating
future
emerging
well
SARS-CoV-2
